TAMPA GENERAL HOSPITAL

Becker's Healthcare spotlights 36 chief innovation officers driving advancements in healthcare through innovative solutions, technologies, and partnerships.

Charles J. Lockwood, MD, MHCM, joined USF Health in 2014, leading transformative growth in research, patient care, and education. Under his tenure, USF Health's research funding surged, patient care revenues increased, and educational programs improved significantly. His leadership was pivotal in establishing USF as a leading academic medical center.

Tampa General Hospital opens outpatient Cellular-Immunotherapy Transplant Unit for aggressive blood cancer patients, offering CAR T-cell and Bone Marrow Transplant therapies under outpatient care, allowing patients to receive treatment at home with 24/7 caregiver support.

Ultra-processed foods linked to higher colon cancer risk by causing chronic gut inflammation, according to a study in 'Gut'. Colon tumors from people with poor diets showed higher pro-inflammatory biochemicals and lower anti-inflammatory substances. Healthy unprocessed foods increase chemicals that suppress inflammation, supporting a 'resolution medicine' approach to cancer prevention.

GE HealthCare to showcase over 40 innovations at RSNA 2024, including AI-enabled technologies like Clarify DL, nCommand Lite, enhanced True PACS, and CareIntellect for Oncology. Notable launches include MINItrace Magni cyclotron, Omni Legend, and Flyrcado PET MPI agent for CAD detection.

Becker's 2024 list highlights hospitals & health systems excelling in oncology, recognized for advanced clinical trials & research. Notable institutions include AdventHealth, Allina Health, Arkansas Children's, Atlantic Health System, Banner MD Anderson Cancer Center, Baylor Scott & White Health, Boston Medical Center, Brown University Health, Children's Health, Children's Hospital Colorado, Children’s Hospital Los Angeles, Children’s Hospital of Orange County, Children's Hospital of Philadelphia, Children's Nebraska, ChristianaCare, City of Hope Comprehensive Cancer Center, Cleveland Clinic, Connecticut Children’s, Covenant Health, Dana-Farber Cancer Institute, Dartmouth Health, DeTar Hospital Cancer Center, Duke Health, El Paso Children's Hospital, Emory Healthcare, Endeavor Health, Fred Hutchinson Cancer Center/UW Medicine, Geisinger, Hackensack Meridian Health, Huntsman Cancer Institute at the University of Utah, Inova, Jefferson Health, Johns Hopkins, Jupiter Medical Center, Keck Medicine of USC, Laredo Medical Center, Lehigh Valley Health Network, MUSC Health, MaineHealth, Massachusetts General Hospital, Mayo Clinic, MedStar, MemorialCare, Memorial Sloan Kettering Cancer Center, Michigan Medicine, Mount Sinai Health System, Nebraska Medicine, New York-Presbyterian Hospital-Columbia and Cornell, Northwestern Medicine, Novant Health, OSF HealthCare, OU Health, Ochsner Health, Ohio State University Comprehensive Cancer Center, Oregon Health & Science University Hospital, Orlando Health, Penn Medicine, Providence Alaska Medical Center, Providence Cancer Institute of Oregon, Providence South Division Cancer Institute, Queen's Health System, RWJBarnabas Health and Rutgers Cancer Institute, Renown Health, Rochester Regional Health, Roper St. Francis Healthcare, Roswell Park Comprehensive Cancer Center, Sanford Health, Sarasota Memorial Health Care System, Scripps Health, St. Jude Children's Research Hospital, Stanford Medicine, Stanford Medicine Children's Health, Sutter Health, Swedish Cancer Institute, Sylvester Comprehensive Cancer Center at University of Miami, Tampa General Hospital, Texas Children's Hospital, UC Davis Health, UCLA Health, UCSF Health, UK HealthCare, UNM Health System, UVA Health, UW Health, UMass Memorial Health, University of Alabama Birmingham Hospital, University of Chicago Medical Center, University of Colorado Cancer Center-UCHealth University of Colorado Hospital, University Hospitals, University of Iowa Health Care, University of Kansas Health System, University of Texas MD Anderson Cancer Center, University of Vermont Health Network, Vanderbilt University Medical Center, Virtua Health, WVU Cancer Institute, WellSpan Health, Yale New Haven Health.

Noman Ashraf discusses the benefits of T-DXd in HER2-mutated and -overexpressing NSCLC, noting higher efficacy in HER2-mutated patients and FDA approval at 5.4 mg/kg due to comparable efficacy and reduced toxicity. Interest grows in using ADCs like T-DXd as frontline therapy, despite the risk of ILD.

T-DXd showed higher ORRs in HER2-mutated NSCLC, with 55% ORR and 17.8 months median overall survival. HER2-overexpressing patients had 26.5% ORR at 6.4 mg/kg and 34.1% at 5.4 mg/kg, with reduced toxicity. ADCs are moving to the frontline setting, with ongoing trials combining T-DXd with standard treatments. ADCs in NSCLC are progressing, with HER2 emerging as a significant target.

Becker's honors healthcare CNOs for tackling nurse staffing shortages, managing budgets, and developing professional growth opportunities. CNOs oversee nursing departments, spearhead innovative patient care initiatives, and bring clinical expertise and executive leadership skills. The list is based on nominations and editorial research, with leaders presented in alphabetical order.

The NSCLC treatment landscape has expanded with FDA approvals, including amivantamab-vmjw plus chemotherapy for EGFR mutations and perioperative durvalumab/nivolumab for resectable NSCLC. Immunotherapy rechallenge is risky due to potential AEs, and ADCs like T-DXd offer alternatives. Amivantamab's dual targeting of EGFR and MET addresses resistance, while perioperative immunotherapy's necessity post-surgery remains uncertain.